The enteric nervous system of several species, including the mouse, rat, guinea pig and
humans, contains cannabinoid CB1receptors that depress gastrointestinal motility, mainly by …

The digestive tract contains endogenous cannabinoids (anandamide and 2-
arachidonylglycerol) and cannabinoid CB1 receptors can be found on myenteric and …

The plant Cannabis has been known for centuries to be beneficial in a variety of
gastrointestinal diseases, including emesis, diarrhea, inflammatory bowel disease and …

Δ9-Tetrahydrocannabinol (the active ingredient of marijuana), as well as endogenous and
synthetic cannabinoids, exert many biological functions by activating two types of …

The therapeutic actions of cannabinoids have been known for centuries. In the last 25 years
this area of research has grown exponentially with the discovery of specific cannabinoid …

In the digestive tract there is evidence for the presence of high levels of endocannabinoids
(anandamide and 2-arachidonoylglycerol) and enzymes involved in the synthesis and …

Cannabinoid receptors of type 1 and 2 (CB1 and CB2), endogenous ligands that activate
them (endocannabinoids), and mechanisms for endocannabinoid biosynthesis and …

Recent work in the field of gastrointestinal pharmacology of cannabinoids has focused on
enteric endocannabinoid and endovanilloid systems and their modulation in …

Recently, the gastrointestinal pharmacology of cannabinoid CB1 receptors has been
extensively explored. We employed western blotting and immunohistochemistry techniques …

From a historical perspective to the present day, all the evidence suggests that activation of
cannabinoid receptors (CBRs) is beneficial for gut discomfort and pain, which are symptoms …